Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-2-fluorenylacetamide, also known as 2-acetylaminofluorene (2-AAF), is a polycyclic aromatic compound historically studied for its profound carcinogenic and mutagenic properties[2][5][6]. This small molecule is used primarily in laboratory research as a model genotoxic carcinogen to induce liver cancer (hepatocarcinogenesis) and other tumors in animal models, notably rodents[2][5]. Its mechanism of action involves metabolic activation by cytochrome P450 enzymes (notably CYP1A2) to form N-hydroxy-2-AAF and other reactive intermediates, which produce DNA adducts leading to mutagenesis and carcinogenesis[5]. It is not used clinically and is handled only for research as a positive control in carcinogenicity studies or mechanistic toxicology[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-2-fluorenylacetamide.